Last update:

Clinical genetics news

Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial

In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with ...

FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival

Researchers at the National Institutes of Health (NIH) and their collaborators at Beren Therapeutics, Thousand Oaks, California, have developed a treatment for infants with Niemann-Pick type C (NPC) disease, which is a rare ...

RNA switch lets drugs control gene therapy protein production

Bioengineers at the University of California San Diego have developed a technology that allows drugs to control when cells produce therapeutic proteins, which could potentially make gene therapies safer and more adaptable ...

Patient age may shape which mutations drive melanoma

Precision medicine for cancer seeks to match treatment to the genetic changes found in a patient's tumor. A new Yale study suggests that for melanoma there may be an important clue to consider: the patient's age.